Fresenius Medical Care (NYSE:FMS) Hits New 12-Month High – What’s Next?

Fresenius Medical Care AG (NYSE:FMS)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $25.06 and last traded at $24.88, with a volume of 262765 shares traded. The stock had previously closed at $24.66.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. StockNews.com assumed coverage on shares of Fresenius Medical Care in a research report on Friday, January 3rd. They set a “strong-buy” rating on the stock. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They set a “buy” rating and a $25.60 target price on the stock. Truist Financial increased their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Finally, Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd.

Fresenius Medical Care Stock Performance

The stock’s fifty day moving average price is $23.14 and its two-hundred day moving average price is $21.18. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The company has a market cap of $14.60 billion, a P/E ratio of 20.57, a P/E/G ratio of 0.82 and a beta of 0.92.

Fresenius Medical Care (NYSE:FMS) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.42 by $0.03. The business had revenue of $5.23 billion during the quarter, compared to the consensus estimate of $5.36 billion. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. During the same quarter in the prior year, the firm earned $0.31 EPS. As a group, equities analysts predict that Fresenius Medical Care AG will post 1.53 earnings per share for the current year.

Hedge Funds Weigh In On Fresenius Medical Care

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Moran Wealth Management LLC raised its stake in shares of Fresenius Medical Care by 47.0% during the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after acquiring an additional 74,621 shares during the last quarter. ABC Arbitrage SA bought a new position in shares of Fresenius Medical Care during the fourth quarter valued at $4,215,000. Quantinno Capital Management LP raised its stake in shares of Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock valued at $2,345,000 after acquiring an additional 48,554 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Fresenius Medical Care by 3.3% during the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock valued at $1,490,000 after acquiring an additional 2,386 shares during the last quarter. Finally, Crossmark Global Holdings Inc. raised its stake in shares of Fresenius Medical Care by 2.2% during the fourth quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company’s stock valued at $1,456,000 after acquiring an additional 1,398 shares during the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.